Publications by authors named "Makoto Takeyama"
Article Synopsis
- The CLOT-COVID Study analyzed 2894 hospitalized patients with COVID-19, focusing on 1738 patients with mild cases who didn’t need oxygen at admission.
- Patients were split into two groups: those receiving prophylactic anticoagulation (326 patients) and those who were not (1412 patients).
- Results showed that those on anticoagulation had higher severity levels during hospitalization and a slightly higher incidence of thrombosis, suggesting that routine use may not be beneficial for all stable patients.
This study aimed to investigate the clinical features of arterial thrombosis and venous thromboembolism (VTE) in coronavirus disease 2019 (COVID-19). The CLOT-COVID Study was a retrospective, multicenter cohort study that enrolled 2,894 consecutively hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We compared the clinical features of arterial thrombosis and VTE.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the association between thrombosis and clinical outcomes in hospitalized COVID-19 patients in Japan, using data from the CLOT-COVID study.
- Patients with thrombosis (55 individuals) experienced significantly higher mortality (23.6% vs. 5.1%) and major bleeding events (23.6% vs. 1.6%) compared to those without thrombosis (2839 individuals).
- Independent risk factors for thrombosis included being male, having elevated D-dimer levels on admission, and severe COVID-19 status, which could help guide treatment decisions for these patients.
Article Synopsis
- The study focused on understanding the use of prophylactic anticoagulation for COVID-19 patients in Japan, highlighting its clinical management strategies.
- Conducted as a multicenter observational study, it involved 2,894 hospitalized patients, ultimately analyzing 2,889 patients based on their anticoagulation treatment.
- Results revealed that the severity of COVID-19 at admission strongly influenced the use of pharmacological thromboprophylaxis and therapeutic dosing, particularly in patients with comorbidities.
Background: Reports of mortality-associated risk factors in patients with the novel coronavirus disease 2019 (COVID-19) are limited.
Methods: We evaluated the clinical features that were associated with mortality among patients who died during hospitalization (n = 158) and those who were alive at discharge (n = 2,736) from the large-scale, multicenter, retrospective, observational cohort CLOT-COVID study, which enrolled consecutively hospitalized COVID-19 patients from 16 centers in Japan from April to September 2021. Data from 2,894 hospitalized COVID-19 participants of the CLOT-COVID study were analyzed in this study.
Background: The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and a potential benefit of anticoagulation therapy has been documented for prevention of thromboembolic events. Bleeding events has also been reported as a notable complication; whereas, the incidence, risks, and clinical impact of bleeding remain unclear.
Method: The CLOT-COVID Study was a nationwide, retrospective, multicenter cohort study on consecutive hospitalized patients with COVID-19 in Japan between April 2021 and September 2021.
Article Synopsis
- Obesity's impact on COVID-19 severity and thrombosis risk was explored in the CLOT-COVID study, involving 2,690 hospitalized patients in Japan from April to September 2021.
- The study found that patients with obesity had more severe COVID-19 symptoms at admission and a higher risk for serious outcomes (like mechanical ventilation) but no significant difference in thrombosis rates compared to non-obese patients.
- Overall, while obesity did not significantly increase the risk of thrombosis, it was linked to worsened COVID-19 severity and worse hospitalization outcomes.
Aim: There is scarce data on the impact of age on clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
Method: The CLOT-COVID Study was a retrospective, multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We divided the entire cohort into five groups according to age strata; -19, 20-39, 40-59, 60-79, and 80- years.
Background: The worsening of coronavirus disease 2019 (COVID-19) severity is a critical issue in current clinical settings and may be associated with the development of thrombosis.
Methods and results: This study used patient data obtained in the CLOT-COVID study, a retrospective multicenter cohort study. The demographics of patients with moderate COVID-19 on admission with and without worsened severity during hospitalization were compared and predictors were identified.
Article Synopsis
- The CLOT-COVID study examined the effectiveness of therapeutic-dose versus prophylactic-dose anticoagulation in critically ill patients with severe COVID-19.
- The study involved 225 patients requiring advanced respiratory support, finding no significant difference in thrombosis rates between the two groups (9.1% for therapeutic vs. 7.8% for prophylactic, P=0.73).
- Ultimately, the results indicated that therapeutic-dose anticoagulation did not provide additional benefits compared to prophylactic dosing for these patients.
To date, there are no large-scale data on the association between D-dimer levels at admission and the occurrence of venous thromboembolism (VTE) in Japanese patients with coronavirus disease 2019 (COVID-19). The CLOT-COVID study was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 across 16 centers in Japan from April 2021 to September 2021. Among 2,894 enrolled patients, 2,771 (96%) had D-dimer levels measured at admission.
View Article and Find Full Text PDFArticle Synopsis
- Data on thrombosis and anticoagulation management in COVID-19 patients is limited, making the CLOT-COVID Study important for understanding treatment challenges.
- The study analyzed 2,894 hospitalized patients in Japan, finding that 43% received thromboprophylaxis, with usage increasing by COVID-19 severity (from 9.8% in mild cases to 97% in severe cases).
- The study revealed low thrombosis rates (1.9%) but higher incidences in severe cases, with major bleeding occurring in 2% of patients and 5.5% dying primarily from respiratory failure.
Article Synopsis
- The CLOT-COVID Study analyzed 2894 hospitalized COVID-19 patients in Japan, focusing on how sex affects thrombosis development.
- Results showed men experienced more severe COVID-19 symptoms at admission and were more likely to receive thrombosis prevention treatment compared to women.
- Men also had a significantly higher incidence of thrombosis during hospitalization, indicating a need for sex-specific management strategies for COVID-19 patients.